Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
04/2003
04/08/2003US6545030 1-heterocycle substituted diarylamines
04/08/2003US6545026 Increase the transactivation of receptor as a ligand of human peroxisome proliferator-activated receptor and exhibit blood glucose-decreasing action and lipid-decreasing action
04/08/2003US6545018 Oxamic acids and derivatives as thyroid receptor ligands
04/08/2003US6545013 2,7-naphthyridine derivatives
04/08/2003US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
04/08/2003US6545002 Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy
04/08/2003US6544998 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
04/08/2003US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
04/08/2003US6544992 Carbonylamino pyrrolidine and piperidine derivatives
04/08/2003US6544988 Tyrosine kinase inhibitors
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003US6544566 For prophylaxis and minimizing development of atherosclerosis
04/08/2003US6544547 Nutritional composition containing methionine
04/08/2003US6544541 Devices and compounds for treating arterial restenosis
04/08/2003US6544525 Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
04/08/2003US6544212 Diabetes management system
04/08/2003CA2184584C Vascular endothelial growth factor 2
04/08/2003CA2065849C Vitamin d analogues
04/07/2003WO2002038152A1 Combination of amines and vanadium (iv)/(v) compounds for the treatment and/or prevention of diabetes mellitus
04/07/2003CA2425192A1 Combination of amines and vanadium (iv)/(v) compounds for the treatment and/or prevention of diabetes mellitus
04/03/2003WO2003027637A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
04/03/2003WO2003027285A1 Dna sequences for human angiogenesis genes
04/03/2003WO2003027275A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027248A2 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003WO2003027246A2 Antagonists
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027116A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
04/03/2003WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027113A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027112A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027111A1 Chemical compounds
04/03/2003WO2003027108A1 Heterocyclic derivatives and their use as hypoglycaemic and hypolipidemic agents
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027084A1 Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
04/03/2003WO2003027080A1 3-substituted-4-pyrimidone derivatives
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027072A1 Process for the preparation of repaglinide
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027065A1 3-desoxy-vitamin d3 analog esters
04/03/2003WO2003027058A1 Sphingolipids
04/03/2003WO2003026695A1 Agonists and antagonists of cylixin for the treatment of metabolic disorders
04/03/2003WO2003026685A1 Agents improving lipid metabolism in liver
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026672A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026661A1 Insulin secretion accelerator and novel pyrimidine derivative
04/03/2003WO2003026659A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003WO2003026656A1 New formulations and use thereof
04/03/2003WO2003026655A1 New formulations and use thereof
04/03/2003WO2003026653A1 Pharmaceutical composition comprising metformin and n-`2-hydroxy-3-(1-piperidinyl)-propoxy! pyridine-1-oxide-3-carboximidoyl chloride
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026637A2 Dosage form for treatment of diabetes mellitus
04/03/2003WO2003026635A2 Improved method of treating the syndrome of type 2 diabetes in humans
04/03/2003WO2003026591A2 Modification of feeding behavior
04/03/2003WO2003026584A2 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026573A2 Screening and selection methods for statin drug combinations
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026561A2 Flavonoids for treatment of diabetes
04/03/2003WO2003026444A1 Mixture of base-containing micronutrient substances
04/03/2003WO2003026408A1 Model animal with overexpression of regucalcin
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002089729A3 Fused heterocyclic compounds
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002066649A3 ANTI-INTERFERON-α ANTIBODIES
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2002030400A1 Solid preparations
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002010357A3 Gsk3 polypeptides
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065179 Diabetic therapy
04/03/2003US20030065173 Therapy for drug abuse
04/03/2003US20030065137 Immunological methods to modulate myostatin in vertebrate subjects
04/03/2003US20030065030 Containing carnosine; therapy for nervous system disorders
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064967 Using probucol ester
04/03/2003US20030064966 Bone disorders; osteoporosis
04/03/2003US20030064963 Aryl boronic acids for treating obesity
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064950 Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
04/03/2003US20030064937 Synergistic mixture of procyanidin and citric acid
04/03/2003US20030064935 Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
1 ... 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 ... 1298